IL17A and breast cancer: demonstrated that the “γδT cell-IL17A-Neutrophil” axis in the breast cancer tumor microenvironment promotes immunosuppression as well as enhancing the breast cancer’s tolerance to high-dose anti-VEGFR2 therapy (98).